-+ 0.00%
-+ 0.00%
-+ 0.00%

Akeso says Phase III HARMONi-GI1 overall survival data for ivonescimab in first-line biliary tract cancer wins ESMO late-breaking slot

PUBT·09/21/2026 23:47:04
Listen to the news
Akeso says Phase III HARMONi-GI1 overall survival data for ivonescimab in first-line biliary tract cancer wins ESMO late-breaking slot
  • Akeso flagged positive overall survival results from a Phase III study of ivonescimab in first-line advanced biliary tract cancer.
  • The data have not been presented yet; they are scheduled as a late-breaking oral at ESMO 2026 in Madrid on Oct. 25, 2026.
  • The trial compared ivonescimab with chemotherapy against durvalumab with chemotherapy, positioning ivonescimab for competitive first-line use.
  • Akeso also outlined broader ESMO 2026 exposure for ivonescimab and cadonilimab, supporting its bispecific antibody portfolio strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609211946PR_NEWS_USPR_____CN53413) on September 21, 2026, and is solely responsible for the information contained therein.